Інформація призначена тільки для фахівців сфери охорони здоров'я, осіб,
які мають вищу або середню спеціальну медичну освіту.


Підтвердіть, що Ви є фахівцем у сфері охорони здоров'я.

"Kidneys" Том 7, №3, 2018

Back to issue

The use of immunobiological monoclonal antibody-based drugs in nephrological practice

Authors: Мельник А.А.
Специализированный медицинский центр «Оптима-фарм», г. Киев, Украина

Categories: Nephrology

Sections: Specialist manual

print version


Summary

При різних захворюваннях нирок успішно застосовується імунобіологічна терапія на основі моноклональних антитіл із різним механізмом дії. До таких лікарських засобів належать: ритуксимаб (взаємодія з рецептором CD20 і елімінування В-клітин), екулізумаб (інгібування розщеплення С5 комплементу), буросумаб (блокування фактора росту фібробластів FGF23), адалімумаб (анти-TNF-α агент), абатацепт (блокує костимуляцію Т-клітин шляхом зв’язування з CD80), фрезолімумаб (нейтралізація TGF-β). Ці лікарські засоби застосовуються при системних захворюваннях нирок, фокально-сегментарному гломерулосклерозі, вовчаковому нефриті, мембранозній нефропатії, при трансплатації нирки.

При различных заболеваниях почек успешно применяется иммунобиологическая терапия на основе моноклональных антител с различным механизмом действия. К таким лекарственным препаратам относятся: ритуксимаб (взаимодействие с рецептором CD20 и элиминирование В-клеток), экулизумаб (ингибирование расщепления С5 комплемента), буросумаб (блокирование фактора роста фибробластов FGF23), адалимумаб (анти-TNF-α агент), абатацепт (блокирует костимуляцию Т-клеток путем связывания с CD80), фрезолимумаб (нейтрализация TGF-β). Эти лекарственные препараты применяются при системных заболеваниях почек, фокально-сегментарном гломерулосклерозе, волчаночном нефрите, мембранозной нефропатии, трансплантации почки.

With various diseases of the kidneys, immunobiological monoclonal antibody-based therapy with a different mechanism of action is successfully used. These drugs include: rituximab (interaction with the CD20 receptor and elimination of B cells), eсulizumab (inhibition of C5 complement clea­vage), burosumab (blocking fibroblast growth factor 23), adalimumab (anti-tumor necrosis factor α agent), abatacept (blocks co-stimulation of T cells by binding to CD80), fresolimumab (neutralization of transforming growth factor β). These drugs are used for systemic kidney diseases, focal segmental glomerulosclerosis, lupus nephritis, membranous nephropathy, kidney transplantation.


Keywords

захворювання нирок; моноклональні антитіла; ритуксимаб; екулізумаб; буросумаб; адалімумаб; абатацепт; фрезолімумаб

заболевания почек; моноклональные антитела; ритуксимаб; экулизумаб; буросумаб; адалимумаб; абатацепт; фрезолимумаб

kidney diseases; monoclonal antibodies; rituximab; eculizumab; burosumab; adalimumab; abatacept; fresolimumab


For the full article you need to subscribe to the magazine.


Bibliography

1. Behring E. Die praktischen Ziele der Blutserumtherapie, 1892.
2. Erhlich P. // Pysiology or medicine 1901–1921. Elsevier Publishing 1. Co., Amsterdam; 1967. P. 304-320.
3. Kohler G., Milstein C. Continuous cultures of fused cells secreting antibody of predefined specificity // Nature. 1975; 256: 495-497. 
4. Smith S.L. Ten years of Orthoclone OKT3 (muromonab-CD3): a review // Journal of transplant coordination: official publication of the North American Transplant Coordinators Organization (NATCO). 1996; 6 (3): 109-119; quiz 119-1. doi: 10.7182/prtr.1.6.3.814513u185493182.
5. Ecker D., Jones S., Levine H. The therapeutic monoclonal antibody market //  Mabs. 2015; 7: 9-14. doi: 10.4161/19420862.2015.989042.
6. Wang S. Advances in the production of human monoclonal antibodies // Antibo Techn Journ. 2011; 1: 1-4.
7. Sheinfeld N. Adalimumab (Humira): a review // J. Drugs Dermatol. 2003 Aug; 2(4): 375-7. 
8. Nelson A.L., Dhimolea E., Reichert J.M. Development trends for human monoclonal antibody therapeutics // Nat. Rev. Drug Discovery. 2010; 9(10): 767-774. doi: 10.1038/nrd3229.
9. Bernett M.J., Karki S.G., Moore G.L., Leung I.W.L., Chen H., Pong E., Nguyen D.H.T., Jacinto J., Zalevsky J., Muchhal U.S. et al. Engineering Fully Human Monoclonal Antibo–dies from Murine Variable Regions // J. Mol. Biol. 2010; 396(5): 1474-1490. doi: 10.1016/j.jmb.2009.12.046.
10. Ansar W., Ghosh S. Monoclonal Antibodies: A Tool in Clinical Research //  Indian J. Clin. Med. 2013; 4: 9-21. doi: 10.4137/IJCM.S11968.
11. Li J., Zhu Z. Research and development of next generation of antibody-based therapeutics // Acta Pharmacol. Sin. 2010; 31(9): 1198-1207. doi: 10.1038/aps.2010.120.
12. Reff M.E., Hariharan K., Braslawsky G. Future of monoclonal antibodies in the treatment of hematologic malignancies // Cancer. Control. 2002; 9(2): 152-66. doi: 10.1177/107327480200900207.
13. Rodrigues M.E., Costa A.R., Henriques M., Azeredo J., Oliveira R. Technological progresses in monoclonal antibody production systems // Biotechnol. Prog. 2010; 26(2): 332-351. doi: 10.1002/btpr.348.
14. Lin W., Kurosawa K., Murayama A., Kagaya E., Ohta K. B-cell display-based one-step method to generate chimeric human IgG monoclonal antibodies // Nucleic. Acids. Res. 2011; 39(3): 1-10. doi: 10.1093/nar/gkq1122.
15. Mak T.M., Hanson B.J., Tan Y.J. Chimerization and characterization of a monoclonal antibody with potent neutralizing activity across multiple influenza A H5N1 clades // Antiviral. Res. 2014; 107(1): 76-83. doi: 10.1016/j.antiviral.2014.04.011.
16. Wang S. Advances in the production of human monoclonal antibodies // Antib. Technol. J. 2011; 1: 1-4. doi.org/10.2147/ANTI.S20195.
17. Chandel P., Harikumar S.L. Pharmaceutical monoclonal antibodies: Production, guidelines to cell engineering and applications // Int. J. Pharm. Sci. 2013; 5(2): 13-20.
18. Harding F.A., Stickler M.M., Razo J., DuBridge R.B. The immunogenicity of humanized and fully human antibodies: Residual immunogenicity resides in the CDR regions // Mabs. 2010; 2(3): 256-265.
19. Bernett M.J., Karki S.G., Moore G.L., Leung I.W.L., Chen H., Pong E., Nguyen D.H.T., Jacinto J., Zalevsky J., Muchhal U.S. et al. Engineering Fully Human Monoclonal Antibo–dies from Murine Variable Regions // J. Mol. Biol. 2010; 396(5): 1474-1490.  doi: 10.1016/j.jmb.2009.12.046.
20. Steinitz M. Human Monoclonal Antibodies // Methods in molecular biology (Clifton N.J.). 2014; 1060: 111-22. 
21. Medecigo M., Manoutcharian K., Vasilevko V., Govezensky T., Munguia M.E., Becerril B., Luz-Madrigal A., Vaca L., Cribbs D.H., Gevorkian G. Novel amyloid-beta specific scFv and VH antibody fragments from human and mouse phage display antibody libraries // J. Neuroimmunol. 2010; 223(1): 104-114. doi: 10.1016/j.jneuroim.2010.03.023
22. Solforosi L., Mancini N., Canducci F., Clementi N., Sautto G.A., Diotti R.A., Clementi M., Burioni R. A phage display vector optimized for the generation of human antibody combinatorial libraries and the molecular cloning of monoclonal antibody fragments // New Microbiol. 2012; 35(3): 289-294.
23. Nelson A., Dhimolea E., Reichert J. Development trends for human monoclonal antibody therapeutics // Nature reviews drug discovery. 2010; 9: 767-774. doi: 10.1038/nrd3229.
24. Ahmad Z.A., Yeap S.K., Ali A.M., Ho W.Y., Alitheen N.B.M., Hamid M. ScFv antibody: Principles and clinical application // Clin. Dev. Immunol. 2012; 1-15. doi: 10.1155/2012/980250.
25. Leget G.A., Czuczman M.S. Use of rituximab, the new FDAapproved antibody // Curr. Opin. Oncol. 1998; 10: 548-551.
26. Edwards J.C., Cambridge G. Sustained improvement in rheumatoid arthritis following a protocol designed to deplete B lymphocytes // Rheumatology. 2001; 40: 205-211. 
27. Turner-Stokes T., Lu T.Y., Ehrenstein M.R. et al. The efficacy of repeated treatment with B-cell depletion therapy in systemic lupus erythematosus: an evaluation // Rheumatology 2011; 50: 1401-1408. doi: 10.1093/rheumatology/ker018.
28. Kado R., Sanders G., McCune W.J. Suppression of normal immune responses after treatment with rituximab // Curr. Opin Rheumatol. 2016; 28: 251-258. doi: 10.1097/BOR.0000000000000272.
29. Seyfizadeh N., Seyfizadeh N., Hasenkamp J. et al. A molecular perspective on rituximab: a monoclonal antibody for B cell non Hodgkin lymphoma and other affections // Crit. Rev. Oncol. Hematol. 2016; 97: 275-290. doi: 10.1016/j.critrevonc.2015.09.001.
30. Ramanath V., Nistala R. & Chaudhary K. Update on the role of rituximab in kidney diseases and transplant // Expert opinion on biological therapy. 2011: 1-11. doi: 10.1517/14712598.2012.646984.
31. Ramos-Casals M., Diaz-Lagares C., Soto-Cardenas M.J. et al. Rituximab therapy in lupus nephritis: current clinical evidence // Clin. Rev. Allergy Immunol. 2011; 40: 159-69. doi: 10.1007/s12016-010-8205-3.
32. Walters G.D., Willis N.S., Craig J.C. Interventions for renal vasculitis in adults. A systematic review // BMC Nephrol. 2010; 11: published online 24 June 2010. doi: 10.1186/1471-2369-11-12.
33. Jones R.B., Tervaert J.W., Hauser T. et al. Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis // N. Engl. J. Med. 2010; 363: 211-20. doi: 10.1056/NEJMoa0909169.
34. Stone J.H., Merkel P.A., Spiera R. et al. Rituximab versus cyclophosphamide for ANCA-associated vasculitis // N. Engl. J. Med. 2010; 363: 221-32. doi: 10.1056/NEJMoa0909905.
35. Guerry M.-J.C.J., Brogan P., Bruce I.N. et al. Recommendations for the use of rituximab in anti-neutrophil cytoplasm antibody-associated vasculitis // Rheumatology. 2012; 51(4): 634-643. doi: 10.1093/rheumatology/ker150.
36. Monti G., Galli M., Invernizzi F. et al. Cryoglobulinaemias: a multi-centre study of the early clinical and laboratory manifestations of primary and secondary disease. GISC. Italian Group for the Study of Cryoglobulinaemias // QJM. 1995; 88: 115-26.
37. Garini G., Allegri L., Lannuzzella F. et al. HCV-rela–ted cryoglobulinemic glomerulonephritis: implications of antiviral and immunosuppressive therapies // Acta Biomed. 2007; 78: 
51-9.
38. Zaja F., De Vita S., Russo D. et al. Rituximab for the treatment of type II mixed cryoglobulinemia // Arthritis Rheum. 2002; 46: 2252-4; author reply 2254-2255. doi: 10.1182/blood-2002-09-2856.
39. Roccatello D., Baldovino S., Rossi D. et al. Rituximab as a therapeutic tool in severe mixed cryoglobulinemia // Clin. Rev. Allergy Immunol. 2008; 34: 111-17.
40. Zaja F., Russo D., Fuga G. et al. Rituximab for the treatment of type II mixed cryoglobulinemia // Haematologica. 1999; 84: 1157-8.
41. Ronco P., Debiec H. Antigen identification in membranous nephropathy moves toward targeted monitoring and new therapy // J. Am. Soc. Nephrol. 2010; 21: 564-9. doi: 10.1681/ASN.2009121220.
42. Ruggenenti P., Cravedi P., Remuzzi G. La–test treatment strategies for membranous nephropathy // Expert. Opin Pharmacother. 2007; 8: 3159-71. doi: 10.1517/14656566.8.18.3159.
43. Cravedi P., Sghirlanzoni M.C., Marasa M., Salerno A., Remuzzi G., Ruggenenti P. Efficacy and safety of Rituximab second-line therapy for membranous nephropathy: a prospective, matched-cohort study // Am. J. Nephrol. 2011; 33: 461-8. doi: 10.1159/000327611.
44. Ruggenenti P., Cravedi P., Sghirlanzoni M.C., Gagliardini E., Conti S., Gaspari F. et al. Effects of Rituximab on morphofunctional abnormalities of membranous glomerulopathy // Clin. J. Am. Soc. Nephrol. 2008; 3: 1652-9. doi: 10.2215/CJN.01730408.
45. Ruggenenti P., Cravedi P., Chianca A., Perna A., Ruggiero B., Gaspari F. et al. Rituximab in idiopathic membranous nephropathy // J. Am. Soc. Nephrol. 2012; 23: 1416-25. doi: 10.1681/ASN.2012020181.
46. Van Husen M., Kemper M.J. New therapies in steroid-sensitive and steroid-resistant idiopathic nephrotic syndrome // Pediatr. Nephrol. 2011; 26: 881-92. doi: 10.1007/s00467-010-1717-5.
47. Guigonis V., Dallocchio A., Baudouin V. et al. Rituximab treatment for severe steroid- or cyclosporine-dependent nephrotic syndrome: a multicentric series of 22 cases // Pediatr. Nephrol. 2008; 23: 1269-79. doi: 10.1007/s00467-008-0814-1.
48. Kamei K., Ito S., Nozu K. et al. Single dose of rituximab for refractory steroid-dependent nephrotic syndrome in children // Pediatr. Nephrol. 2009; 24: 1321-8.
49. Prytula A., Iijima K., Kamei K. et al. Rituximab in refractory nephrotic syndrome // Pediatr. Nephrol. 2010; 25: 461-8. doi: 10.1007/s00467-009-1376-6.
50. Gulati A., Sinha A., Jordan S.C. et al. Efficacy and safety of treatment with rituximab for difficult steroid-resistant and -dependent nephrotic syndrome: multicentric report // Clin. J. Am. Soc. Nephrol. 2010; 5: 2207-12.
51. Fuchinoue S., Ishii Y., Sawada T. et al. The 5-year outcome of ABO-incompatible kidney transplantation with rituximab induction // Transplantation. 2011; 91: 853-7.
52. Becker Y.T., Becker B.N., Pirsch J.D., Sollinger H.W. Rituximab as treatment for refractory kidney transplant rejection // Am. J. Transplant. 2004; 4: 996-1001. doi: 10.1111/j.1600-6143.2004.00454.x.
53. Imamura R., Ishiguro S., Shi Y. et al. ABO-incompatible kidney transplantation with anti-CD20 monoclonal antibodies, intravenous immunoglobulin and plasmapheresis without splenectomy: a case report // Xenotransplantation. 2006; 13: 133-5.
54. Sonnenday C.J., Warren D.S., Cooper M. et al. Plasmapheresis, CMV hyperimmune globulin, and anti-CD20 allow ABO-incompatible renal transplantation without splenectomy // Am. J. Transplant. 2004; 4: 1315-22. doi: 10.1111/j.1600-6143.2004.00507.x.
55. Tyden G., Kumlien G., Genberg H. et al. ABO incompa–tible kidney transplantations without splenectomy, using antigen-specific immunoadsorption and rituximab // Am. J. Transplant. 2005; 5: 145-8. doi: 10.1111/j.1600-6143.2004.00653.x.
56. Toki D., Ishida H., Horita S. et al. Impact of low-dose rituximab on splenic B cells in ABO-incompatible renal transplant recipients // Transpl. Int. 2009; 22: 447-54. doi: 10.1111/j.1432-2277.2008.00821.x.
57. Davis J. Eculizumab // Am. J. Health Syst. Pharm. 2008; 65: 1609e15.
58. Rother R.P., Rollins S.A., Mojcik C.F. et al. Discovery and development of the complement inhibitor eculizumab for the treatment of paroxysmal nocturnal hemoglobinuria // Nat. Biotechnol. 2007; 25: 1256-1264. doi: 10.1038/nbt1344.
59. Scheiring J., Rosales A., Zimmerhackl L.B. Clinical practice: today’s understanding of the haemolytic uraemic syndrome // Eur. J. Pediatr. 2010; 169: 7-13. 
60. Waters A.M., Licht C. aHUS caused by complement dysregulation: new therapies on the horizon // Pediatr. Nephrol. 2011; 26: 41-57. doi: 10.1007/s00467-010-1556-4.
61. Gruppo R.A., Rother R.P. Eculizumab for congenital aty–pical hemolytic-uremic syndrome [letter] // N. Engl. J. Med. 2009; 360: 544-6. doi: 10.1056/NEJMc0809959.
62. Lapeyraque A., Frémeaux-Bacchi V., Robitaille P. Efficacy of eculizumab in a patient with factor-H-associated atypical hemolytic uremic syndrome // Pediatr. Nephrol. 2011; 26: 621-4. doi: 10.1007/s00467-010-1719-3.
63. Davin J., Gracchi V., Bouts A. et al. Maintenance of kidney function following treatment with eculizumab and discontinuation of plasma exchange after a third kidney transplant for atypical hemolytic uremic syndrome associated with a CFH mutation // Am. J. Kidney Dis. 2010; 55: 708-11. doi: 10.1053/j.ajkd.2009.08.011.
64. FDA approves first therapy for rare inherited form of rickets, x-linked hypophosphatemia (Press release). FDA 17 April 2018.
65. Klinkhoff A. Biological agents for rheumatoid arthritis: targeting both physical function and structural damage // Drugs. 2004; 64: 1267-1283.
66. D’Agati V.D. Renal disease in systemic lupus erythematosus, mixed connective tissue disease, Sjogren’s syndrome, and rheumatoid arthritis / Jennette J.C., Olsen J.L., Schwartz M.M. et al., eds. // Heptinstall’s Pathology of the Kidney. Vol. 1. — Lippincott-Raven: PA, 1998. — 541-624.
67. Hueber A.J., Tunc A., Schett G., Manger B. Anti-tumour necrosis factor alpha therapy in patients with impaired renal function [letter] // Ann. Rheum. Dis. 2007; 66: 981-2. doi: 10.1136/ard.2006.069211.
68. Cho S.K., Sung Y.K., Park S., Bae S.C. Etanercept treatment in rheumatoid arthritis patients with chronic kidney failure on predialysis // Rheumatol. Int. 2010; 30: 1519-22. doi: 10.1007/s00296-009-1108-z.
69. Kobak S. Efficacy and safety of adalimumab in a patient with ankylosing spondylitis on peritoneal dialysis // Rheumatol. Int. 2012; 32: 1785-7. doi: 10.1007/s00296-010-1457-7.
70. Hammoudeh M. Infliximab treatment in a patient with rheumatoid arthritis on haemodialysis // Rheumatology (Oxford). 2006; 45: 357-9. doi: 10.1093/rheumatology/kei264.
71. Joy M.S., Gipson D.S., Powell L., MacHardy J., Jennette J.C., Vento S. et al. Phase 1 trial of adalimumab in focal segmental glomerulosclerosis (FSGS): II. Report of the FONT (Novel Therapies for Resistant FSGS) study group // Am. J. Kidney Dis. 2010; 55: 50-60. doi: 10.1053/j.ajkd.2009.08.019.
72. Bristol-Myers Squibb Orencia® (abatacept). US Prescri–bing Information. — NJ: Princeton, 2008.
73. Yamada A., Salama A.D., Sayegh M.H. The role of novel T cell costimulatory pathways in autoimmunity and transplantation // J. Am. Soc. Nephrol. 2002; 13: 559-575.
74. Ostor A.J. Abatacept: a T-cell co-stimulation modulator for the treatment of rheumatoid arthritis // Clin. Rheumatol. 2008; 27: 1343-1353. doi: 10.1007/s10067-008-0964-3.
75. Yu C.-C., Fornoni A., Weins A., Hakroush S., Maiguel D., Sageshima J. et al. Abatacept in B7-1-positive proteinuric kidney disease // N. Engl. J. Med. 2013; 369: 2416-23. doi: 10.1056/NEJMoa1304572.
76. Dennler S., Goumans M.J., ten Dijke P. Transforming growth factor beta signal transduction // J. Leukoc. Biol. 2002; 71: 731-740.
77. Yu L., Border W.A., Huang Y., Noble N.A. TGF-beta isoforms in renal fibrogenesis // Kidney Int. 2003; 64: 844-856. doi: 10.1046/j.1523-1755.2003.00162.x.
78. Trachtman H., Fervenza F.C., Gipson D.S., Heering P., Jayne D.R., Peters H. et al. A phase 1, single-dose study of fresolimumab, an anti-TGF-b antibody, in treatment-resistant primary focal segmental glomerulosclerosis // Kidney Int. 2011; 79: 1236-43. doi: 10.1038/ki.2011.33.
79. Vincenti F., Fervenza F., Campbell K. A Phase 2, Double-Blind, Placebo-Controlled, Randomized Study of Fresolimumab in Patients With Steroid-Resistant Primary Focal Segmental Glomerulosclerosis // Kidney Int. Rep. 2017; 2: 800-810. doi.org/10.1016/j.ekir.2017.03.011.
80. Trachtman H., Goyal S., Finn P. et al. Neutralizing –TGF-b in fibrotic renal disorders: focus on fresolimumab // Drugs Future. 2012; 37: 787-794.
81. Dorner T., Shock A., Smith K.G. CD22 and autoimmune disease // Int. Rev. Immunol. 2012; 31: 363-78.

Similar articles

Inhibition of bacterial virulence factors as a method of treating bacterial pneumonia
Authors: Абатуров А.Е.(1), Крючко Т.А.(2)
(1) — ГУ «Днепропетровская медицинская академия МЗ Украины», г. Днепр, Украина
(2) — ВГУЗУ «Украинская медицинская стоматологическая академия», г. Полтава, Украина

"Child`s Health" Том 13, №2, 2018
Date: 2018.05.24
Categories: Pediatrics/Neonatology
Sections: Specialist manual
Immunobiological drugs in the treatment of rheumatic diseases
Authors: Мельник А.А.
Специализированный медицинский центр «Оптима-фарм», г. Киев, Украина

"Kidneys" Том 8, №3, 2019
Date: 2019.09.04
Categories: Nephrology
Sections: Specialist manual
Гепатит С-вирусная инфекция у нефрологических пациентов
Authors: Lionel Rostaing, MD, PhD1–3, Jacques Izopet, PharmD, PhD2–4, Nassim Kamar, MD, PhD1–3 1Department of Nephrology, Dialysis and Organ Transplantation, CHU Rangueil, Toulouse, France / 1Кафедра нефрологии, диализа и трансплантации органов, CHU Rangueil, Тулуза, Франция 2INSERM U1043, IFR–BMT, CHU Purpan, Toulouse, France / 2INSERM U1043, IFR-BMT, CHU Purpan, Тулуза, Франция 3Université Paul Sabatier, Toulouse, France / 3Университет Поля Сабатье, Тулуза, Франция 4Department of Virology, CHU Purpan, Toulouse, France / 4Отдел вирусологии, CHU Purpan, Тулуза, Франция
"Kidneys" 1 (03) 2013
Date: 2013.03.14
Categories: Nephrology
Sections: Specialist manual
Clinical case of successful treatment of Goodpasture syndrome with rituximab
Authors: Головач И.Ю.(1), Яременко О.Б.(2), Стельмащук В.П.(1), Матийко В.Н.(1), Чипко Т.М.(1), Корочев А.В.(1), Михальченко Е.М.(1), Михальская Л.В.(1)
(1) — Клиническая больница «Феофания» Государственного управления делами, г. Киев, Украина
(2) — Национальный медицинский университет им. А.А. Богомольца, г. Киев, Украина

"Kidneys" Том 7, №2, 2018
Date: 2018.04.10
Categories: Nephrology
Sections: Clinical researches

Back to issue